Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Seres Therapeutics Inc (NASDAQ: MCRB) closed at $0.88 in the last session, down -1.09% from day before closing price of $0.89. In other words, the price has decreased by -$1.09 from its previous closing price. On the day, 1.72 million shares were traded. MCRB stock price reached its highest trading level at $0.9099 during the session, while it also had its lowest trading level at $0.85.
Ratios:
We take a closer look at MCRB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.12 and its Current Ratio is at 1.12. In the meantime, Its Debt-to-Equity ratio is 3.91 whereas as Long-Term Debt/Eq ratio is at 3.56.
On April 21, 2023, JP Morgan started tracking the stock assigning a Neutral rating and target price of $7.JP Morgan initiated its Neutral rating on April 21, 2023, with a $7 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 18 ’24 when DesRosier Thomas sold 878 shares for $0.54 per share. The transaction valued at 475 led to the insider holds 135,192 shares of the business.
von Moltke Lisa sold 977 shares of MCRB for $528 on Nov 18 ’24. The insider now owns 32,415 shares after completing the transaction at $0.54 per share. On Nov 18 ’24, another insider, Shaff Eric D., who serves as the CEO and President of the company, sold 2,505 shares for $0.54 each. As a result, the insider received 1,355 and left with 170,389 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MCRB now has a Market Capitalization of 150300656 and an Enterprise Value of 145665008. For the stock, the TTM Price-to-Sale (P/S) ratio is 2505.06 while its Price-to-Book (P/B) ratio in mrq is 6.26. Its current Enterprise Value per Revenue stands at 1.153 whereas that against EBITDA is -3.991.
Stock Price History:
Over the past 52 weeks, MCRB has reached a high of $2.05, while it has fallen to a 52-week low of $0.54. The 50-Day Moving Average of the stock is 11.35%, while the 200-Day Moving Average is calculated to be -0.19%.
Shares Statistics:
According to the various share statistics, MCRB traded on average about 3.67M shares per day over the past 3-months and 2909160 shares per day over the past 10 days. A total of 170.20M shares are outstanding, with a floating share count of 124.81M. Insiders hold about 26.90% of the company’s shares, while institutions hold 23.58% stake in the company. Shares short for MCRB as of 1732838400 were 17381399 with a Short Ratio of 4.73, compared to 1730332800 on 17852612. Therefore, it implies a Short% of Shares Outstanding of 17381399 and a Short% of Float of 13.63.
Earnings Estimates
A comprehensive evaluation of Seres Therapeutics Inc (MCRB) is underway, with the input of 4.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.12 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.11 and -$0.94 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.41, with 4.0 analysts recommending between -$0.02 and -$0.82.
